- Stereotactic body radiotherapy (SBRT) delays treatment escalation in men with oligometastatic prostate cancer regardless of the number of lesions.
- No associated grade 3 toxicity was observed.
Why this matters
- Findings suggest SBRT can delay treatment escalation and improve QoL in selected patients.
- Interim analysis of phase 2 TRANSFORM study of 199 men with prostate cancer (≤5 lesions) previously treated with definitive local treatment who received fractionated SBRT.
- Funding: Epworth Medical Foundation; E.J. Whitten Prostate Cancer Foundation.
- Median follow-up time, 35.1 months.
- 51.7% of patients did not require treatment escalation at 2 years.
- Median treatment escalation-free survival time was 27.1 months.
- Rising PSA and progression were the most common reasons for treatment escalation.
- Prior androgen deprivation therapy use (HR, 1.97; P=.005) and increasing age (HR, 1.39; P<.001 were associated with treatment escalation.>
- Treatment escalation was similar in patients with 1-3 vs 4-5 lesions.
- 75.0% of patients showed PSA decline after SBRT, and 6 had undetectable PSA level.
- No late grade 3 toxicities were reported.
- Lack of a control group.